<DOC>
	<DOC>NCT00582738</DOC>
	<brief_summary>This study will assess the efficacy of everolimus as an inhibitor of fibrosis progression in liver transplant patients who have a recurrence of hepatitis C viral infection in the transplant</brief_summary>
	<brief_title>Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male or female patients 18 65 years of age Recipients of deceased or living donors Patients who had undergone primary liver transplantation at least 6 months before enrolment Recurrent Hepatitis C viral infection and histologically confirmed liver fibrosis (stage IIV in the IshakKnodell scale) obtained at baseline or within the previous 6 months to the date of enrolment Patients receiving tacrolimus or cyclosporine microemulsion with or without Mycophenolic acid (MPA), with or without steroids. Absence of acute rejection episodes within the previous 6 months to the date of enrolment Patient in whom an allograft biopsy will not be contraindicated Patient willing and capable of giving written informed consent for study participation and able to participate in the study for 24 months Patients with Hepatocellular carcinoma (HCC) within the University California, San Francisco (UCSF) Criteria and no recurrence for at least 18 months after OLT. Recipients of multiple organ transplants or patients who have undergone retransplantation Current biliary complications History of drug or alcohol abuse within 1 year before enrolment Patients treated with antihepatitis C virus treatment at the time of enrollment or within the previous month to the date of enrolment Coinfection with Hepatitis B virus (HBV) or Human Immunodeficiency Virus (HIV) Patients with Leukocyte count (WBC) &lt; 3000/mm3, platelet count &lt; 75000/mm3 or Hemoglobin (Hb) &lt; 8 g/dl Patients with proteinuria &gt;1g/24 hours Patient with a current severe systemic infection Other protocol defined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Fibrosis progression</keyword>
	<keyword>recurrent hepatitis C</keyword>
	<keyword>viral infection</keyword>
	<keyword>liver transplant recipients</keyword>
	<keyword>everolimus</keyword>
	<keyword>Hepatitis C recurrence after orthotopic liver transplantation (OLT)</keyword>
</DOC>